Although no definite clinical data on CAR T-cell therapy has been published yet for its use in bladder cancer, several early phase I/II clinical trials are ongoing targeting the prostate-specific membrane antigen (PSMA), the human epidermal growth factor receptor 2 (HER2), Nectin4/FAP, NKG2D ligands, and the receptor tyrosine kinase-like orphan receptor 2 (ROR2), respectively (NCT03185468, NCT03740256, NCT 03932565, NCT03018405, NCT039600601). Here, FOLH1 is linked to urinary bladder cancer.